Ramipril
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Ramipril
- Ramipril: From Unspecified Original Indication to Pulmonary Hypertension with Unclear Multifactorial Mechanism
Ramipril: From Unspecified Original Indication to Pulmonary Hypertension with Unclear Multifactorial Mechanism
One-Sentence Summary
Ramipril is an ACE inhibitor; its original approved indication is not recorded in this evidence pack. The TxGNN model’s top prediction suggests possible relevance to Pulmonary Hypertension with Unclear Multifactorial Mechanism, but this direction currently has 0 clinical trials and 0 supporting publications — the prediction score is high, but the evidence base is empty.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (no original_indications data recorded) |
| Predicted New Indication | Pulmonary Hypertension with Unclear Multifactorial Mechanism |
| TxGNN Prediction Score | 99.93% (rank 1659) |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available for ramipril in this evidence pack (flagged as a High-severity data gap, DG002). Based on known pharmacological class, ramipril is an ACE inhibitor (ACEI). Mechanistically, ACE inhibitors reduce angiotensin II production, which in theory could lower pulmonary vascular resistance and reduce pulmonary vasoconstriction — a plausible, if indirect, biological rationale for a role in pulmonary hypertension.
However, the target indication here is specifically defined as pulmonary hypertension “with unclear multifactorial mechanism” — meaning the disease’s own pathophysiology is not well characterized. This makes it inherently difficult to construct a strong biological argument connecting ACE inhibition to this particular PH subtype, and no clinical or preclinical evidence currently exists to support the link.
Because original_indications is empty in this evidence pack, no direct comparison can be made between ramipril’s original approved use and this predicted indication. Resolving this data gap (see Conclusion) is necessary before the mechanistic rationale can be properly evaluated.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
India Market Information
No registration records available — Ramipril currently holds 0 licenses and is not marketed in India per this evidence pack.
Safety Considerations
Drug Interactions: 283 documented interactions are recorded for ramipril in the DDI database. Notable interactions include:
- Major severity: Potassium citrate, Potassium bicarbonate — combined use with an ACE inhibitor raises hyperkalemia risk.
- Moderate severity: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), sulfonylureas (chlorpropamide, glimepiride), metformin, corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), acetylsalicylic acid, morphine, bupropion, dronabinol, and bowel-prep agents (picosulfuric acid, polyethylene glycol with electrolytes).
Key warnings and contraindications are not available in this evidence pack (flagged as Blocking data gap DG001 — TFDA package insert not yet retrieved).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction carries a high TxGNN score but zero supporting clinical trials or literature (Evidence Level L5), and the target disease’s own mechanism is described as “unclear,” making biological plausibility hard to establish. Critical drug-level data (original indication, detailed MOA, regulatory warnings/contraindications) are also missing, blocking a full safety assessment (S1).
To proceed, the following is needed:
- Resolve Blocking data gap DG001: retrieve TFDA/regulatory package insert (warnings & contraindications)
- Resolve High-priority data gap DG002: retrieve detailed MOA via DrugBank API
- Recover original approved indication(s) for ramipril to enable indication-relationship analysis
- Consider re-evaluating lower-ranked but better-evidenced candidates in this same evidence pack — e.g., rank 10 (cerebral artery occlusion), which has Evidence Level L3 with a completed Phase 2 trial (NCT00005928) and 5 supporting mechanistic/clinical studies, may represent a more actionable next step than the current top-ranked candidate.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.